Literature DB >> 18358605

Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro.

Takashi Kasai1, Takahiko Tokuda, Nozomi Yamaguchi, Yoshihisa Watanabe, Fuyuki Kametani, Masanori Nakagawa, Toshiki Mizuno.   

Abstract

Neurosin is one of the serine proteases predominantly expressed in the central nervous system. Neurosin is presumed to play an important role in the degradation of alpha-synuclein (alpha-syn), since a previous study showed that neurosin degrades alpha-syn, inhibits polymerization of alpha-syn in vitro, and exists in Lewy bodies. However, the details of alpha-syn degradation by neurosin are little known. We investigated neurosin-mediated cleavage of alpha-syn by immunoblotting and liquid chromatography-ion trap mass spectrometry (LC/MS/MS). We also compared alpha-syn degradation by neurosin between phosphorylated and non-phosphorylated forms of alpha-syn, and between mutant and wild-type alpha-syn. Neurosin cleaved alpha-syn at specific sites. The major cleavage site was localized between Lys80 and Thr81 within the NAC region (E61 to V95), which is important for alpha-syn aggregation, and accordingly may preclude alpha-syn polymerization. Meanwhile, alternative, minor forms of processing also occur. They conserve the NAC region with truncation of the C-terminal region, and accordingly may contribute to alpha-syn polymerization. Phosphorylated alpha-syn was more resistant to degradation by neurosin than non-phosphorylated alpha-syn. The A30P mutant was more resistant to degradation than the wild-type and other alpha-syn mutants. This resistance to neurosin-mediated degradation of phosphorylated alpha-syn and the A30P mutant, which are, respectively, posttranslational and genetic factors related to the development of Parkinson's disease (PD), provides supporting evidence that neurosin is involved in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18358605     DOI: 10.1016/j.neulet.2008.02.057

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  31 in total

1.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

Authors:  Brian Spencer; Sarah Michael; Jay Shen; Kori Kosberg; Edward Rockenstein; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 2.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

Review 3.  Cell Biology and Pathophysiology of α-Synuclein.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

Review 4.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Authors:  Heather E Allen Reish; David G Standaert
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

Review 5.  The emerging role of α-synuclein truncation in aggregation and disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

6.  Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease.

Authors:  Kwang Soo Kim; Yu Ree Choi; Ji-Young Park; Jung-Ho Lee; Dong Kyu Kim; Seung-Jae Lee; Seung R Paik; Ilo Jou; Sang Myun Park
Journal:  J Biol Chem       Date:  2012-05-22       Impact factor: 5.157

7.  Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy.

Authors:  Kiren Ubhi; Phil Hyu Lee; Anthony Adame; Chandra Inglis; Michael Mante; Edward Rockenstein; Nadia Stefanova; Gregor K Wenning; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2009-09       Impact factor: 4.164

Review 8.  α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.

Authors:  Katrin Beyer; Aurelio Ariza
Journal:  Mol Neurobiol       Date:  2012-08-25       Impact factor: 5.590

9.  Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.

Authors:  Dora Games; Elvira Valera; Brian Spencer; Edward Rockenstein; Michael Mante; Anthony Adame; Christina Patrick; Kiren Ubhi; Silke Nuber; Patricia Sacayon; Wagner Zago; Peter Seubert; Robin Barbour; Dale Schenk; Eliezer Masliah
Journal:  J Neurosci       Date:  2014-07-09       Impact factor: 6.167

10.  Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms.

Authors:  Hyesook Yoon; Maja Radulovic; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2018-09-25       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.